SER
AMEXSerina Therapeutics Inc.
Price$1.94+0.26 (+15.48%)
2026-03-042026-06-05
News · 26 weeks550%
2025-12-142026-06-07
Mix3190d
- SEC Filings13(42%)
- Insider11(35%)
- Other7(23%)
Latest news
25 items- SECSEC Form EFFECT filed by Serina Therapeutics Inc.EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERChief Executive Officer Ledger Steven A was granted 10,100 shares (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by SVP, CMC & Formulation Tenjarla Srini4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Ledger Steven A4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Curhan Gregory S4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Moreadith Randall4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Wilson Karen J bought $37,000 worth of shares (20,000 units at $1.85) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Marshall Richard Peter bought $20,102 worth of shares (12,183 units at $1.65) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSEC Form S-3 filed by Serina Therapeutics Inc.S-3 - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesPhase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support continued advancement of SER-252 – HUNTSVILLE, May 14, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates. "With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form 10-Q filed by Serina Therapeutics Inc.10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form SCHEDULE 13G filed by Serina Therapeutics Inc.SCHEDULE 13G - Serina Therapeutics, Inc. (0001708599) (Subject)
- SECSEC Form DEFA14A filed by Serina Therapeutics Inc.DEFA14A - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form DEF 14A filed by Serina Therapeutics Inc.DEF 14A - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERSEC Form 4 filed by Bailey Gregory4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Venkatesan Jay4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSEC Form PRE 14A filed by Serina Therapeutics Inc.PRE 14A - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads – HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 5th LNP Formulation & Process Development Summit in Boston, MA. Entitled "Novel Lipid Nanoparticles Built
- PRSerina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanHUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported that the NYSE American LLC ("NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide. "We are pleased that NYSE American has accepted our plan to regain compliance with its continued listing standards," said Steve Ledger, CEO of Serina. "We remain focused on executing the SER-252 clinical program and advancing our P
- SECAmendment: SEC Form 10-K/A filed by Serina Therapeutics Inc.10-K/A - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form S-8 filed by Serina Therapeutics Inc.S-8 - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead," said Steve Ledger, CEO of S
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
SER FAQ
6 questionsWhere does SER stock trade?
Serina Therapeutics Inc. (SER) is listed on AMEX.What sector and industry is SER in?
Serina Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Serina Therapeutics Inc. go public?
Serina Therapeutics Inc. (SER) completed its IPO in 2018.What are analysts saying about SER?
Serina Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1500.00 price target on 2025-07-14. Recent price targets cluster around $1500.00.What companies are similar to SER?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SER side-by-side with any of them on Quantisnow.How can I track SER on Quantisnow?
Quantisnow aggregates Serina Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SER to receive live email and push alerts on every new disclosure.